^
Association details:
Biomarker:KIT V559D
Cancer:Melanoma
Drug:imatinib (c-KIT inhibitor, Bcr-abl inhibitor, PDGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

Excerpt:
In vitro drug sensitivity for imatinib, dasatinib and nilotinib of Ba/F3 stable transformants expressing KITL576P and KITV559D: (a,b) proliferation inhibition, (c,d) increased apoptosis, and (e,f) decrease in KIT phosphorylation by immunoprecipitation.
DOI:
10.1002/ijc.22681